XML 18 R6.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Cash flows from operating activities    
Net loss $ (111,894) $ (45,532)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities    
Loss (gain) from Continuation Advances 52,000 (34,000)
Depreciation 4,943 4,827
Amortization of intangible assets 154  
Amortization of operating lease right-of-use assets 2,403 2,127
Amortization of debt discount and financing costs 381 129
Stock-based compensation 54,417 12,258
Amortization (accretion) from investment premium (discount) 3,107 (141)
Deferred income taxes (94,824)  
Changes in assets and liabilities    
Accounts receivable (6,871) 3,428
Inventory (5,453) (2,988)
Prepaid expenses and other assets (1) 216
Accounts payable 196 (2,955)
Accrued expenses 10,267 1,646
Deferred revenue 17,930 (818)
Operating lease liabilities (3,231) (2,791)
Other liabilities (2,996) 360
Deferred gain from Reverse Termination fee   98,000
Net cash provided by (used in) operating activities (79,472) 33,766
Cash flows from investing activities    
Purchase of property and equipment (3,089) (972)
Purchase of investments (857,421) (234,555)
Sales of investments 212,734  
Maturities of investments 223,285 114,700
Net cash used in investing activities (744,284) (120,827)
Cash flows from financing activities    
Continuation Advances (52,000) 34,000
Notes payable principal payoff   (16,000)
Proceeds from issuance of Convertible Senior Notes, net of issuance costs 895,536  
Proceeds from issuance of common stock under equity offerings, net of issuance costs 294,846 93,788
Proceeds from issuance of common stock from equity plans 30,121 14,174
Other (246)  
Net cash provided by financing activities 1,168,257 125,962
Net increase in cash and cash equivalents and restricted cash 344,501 38,901
Cash and cash equivalents and restricted cash at beginning of period 85,947 33,627
Cash and cash equivalents and restricted cash at end of period 430,448 72,528
Cash and cash equivalents at end of period 425,388 69,028
Restricted cash at end of period 5,060 $ 3,500
Supplemental disclosure of non-cash investing and financing activities    
Issuance of common stock in acquisition of Omniome 237,884  
Circulomics, Inc [Member]    
Cash flows from investing activities    
Cash paid for purchase of business acquisition, net of cash acquired (28,560)  
Omniome, Inc [Member]    
Cash flows from investing activities    
Cash paid for purchase of business acquisition, net of cash acquired $ (291,233)